Anti-ErbB2 mAb H2-18 induces PCD in ErbB2-overexpresing breast cancer cells.
H2-18 plus saracatinib induce a greater PCD compared with either drug alone.
H2-18 and saracatinib synergistically inhibit in vitro cell proliferation of breast cancer cells.
H2-18 plus saracatinib exert a greater in vivo antitumor activity than either drug alone.